The latest price of larotrectinib in 2025 published on the whole network

Larotinib is a targeted drug used to treat solid tumors carrying NTRK gene fusions. It can block the signaling pathway mediated by TRK and inhibit the activity of TRK to block the growth and spread of tumor cells. Its price, dosing guidelines, and contraindications are critical to patients.

The latest price of larotrectinib in 2025 published on the entire network

varies depending on the brand, specification and purchase channel. Patients need to choose the appropriate drug according to their own economic conditions. The following will be analyzed from two aspects: the price of original drugs and the price of generic drugs.

Original drug price

The original drug of larotrectinib is produced by Bayer. The original drug of larotrectinib has been included in medical insurance. The winning price of medical insurance ranges from approximately US$2,008 to US$4,358. The price after reimbursement will be lower. Patients can reduce their out-of-pocket expenses through medical insurance reimbursement. The specific reimbursement ratio varies by region.

Price of generic drugs

The price of the generic version of larotinib is relatively low. The specification of larotinib imitated by Everest in Bangladesh is 100 mg * 30 pills per box, and the price is about US$553; the specification of larotinib imitated by Lucius in Laos is 100 mg * 30 pills per box, and the price is about US$208. These generic drugs are basically the same as the original drugs in dosage and efficacy, and are suitable for patients with limited economic conditions.

Understanding the latest price of larotrectinib in 2025 will help patients choose the appropriate drug according to their own economic conditions, and at the same time, they can better plan the cost of treatment.

Larotinib Medication Guide

Larotinib Medication Guide includes dosage, dosing frequency, and dosing recommendations for special populations.

Adult Dosage

The recommended dose for adult patients is 100 mg twice daily until disease progression or unacceptable toxicity occurs. Patients should strictly follow their doctor's recommendations and avoid adjusting the dosage on their own.

Pediatric Dosage

Dosage in pediatric patients is based on body surface area (BSA), with the recommended dose being 100 mg/m² twice daily, with a maximum dose of 100 mg/dose. Pediatric patients should use the drug under the guidance of a doctor and have their body surface area measured regularly.

Dose adjustment for special populations

For patients with hepatic impairment, the starting dose should be reduced by 50% in patients with moderate to severe hepatic impairment. No dosage adjustment is necessary in patients with renal impairment. Dose adjustments are also not recommended in elderly patients.

Following the medication guidelines for larotrectinib can help patients better control their condition and reduce the occurrence of side effects.

Contraindications for larotrectinib

Patients need to pay attention to some contraindications when using larotrectinib. The following will explain the two aspects of allergic reactions and contraindications for special groups.

Allergic Reaction

Patients who have an allergic reaction to larotrectinib or any excipient are prohibited from using this drug. Patients should inform their doctor of their allergic history before taking the medication to avoid severe allergic reactions.

Contraindications for special groups

Pregnant and breastfeeding women should avoid using larotrectinib because the drug may cause harm to the fetus or infant. Women of childbearing age should take effective contraceptive measures while using larotrectinib, and male patients should also take corresponding contraceptive measures.

Understanding the contraindications for larotrectinib can help patients make better use of the drug and avoid unnecessary risks.